|
|
|
|
|
|
Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
ClinicalTrials.gov Identifier: | NCT00000516 |
To determine if enalapril treatment of left ventricular dysfunction (LVD) due to ischemic or hypertensive heart disease led to reduced mortality and morbidity in symptomatic and asymptomatic patients. There were a Prevention Trial, a Treatment Trial, and a registry.
Condition | Intervention | Phase |
Cardiovascular Diseases Coronary Disease Heart Diseases Heart Failure Hypertension Myocardial Ischemia |
Drug: enalapril |
Phase III |
MedlinePlus related topics: | Heart Diseases Heart Failure High Blood Pressure |
Drug Information available for: | Enalapril Enalapril maleate Enalaprilat |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Placebo Control |
Ages Eligible for Study: | 21 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Men and women, ages 21 to 80. Subjects were asymptomatic or symptomatic and had ejection fractions equal to or below 35 percent.
Study ID Numbers: | 35 |
First Received: | October 27, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00000516 |
Health Authority: | United States: Federal Government |
|
|
|